0001728117-26-000032
SEC filingRevenue grew 71.5% to $17.0M from heightened research and development and pre-commercial services, while operating losses expanded 21.9% to -$44.9M reflecting sustained biotech investment in seralutinib amid uncertain regulatory paths.
Revenue for Q1 FY2026 reached $17.0 million, up 71.5% from $9.9 million in the prior year quarter. This acceleration stems from increased research and development and pre-commercial services, as noted in management's discussion, supporting Gossamer Bio's pipeline advancement particularly for seralutinib. Such growth highlights the company's strategic collaborations that offset the typical pre-commercial revenue constraints in biotech.
Operating income deteriorated to -$44.9 million from -$36.8 million year-over-year, a 21.9% widening. This reflects the company's focus on deploying personnel and facility resources across all research and development activities, including the inherently unpredictable preclinical and clinical development of seralutinib. Investors should note that these investments sustain the path toward potential regulatory clarity, though timing and costs remain uncertain.
Net income followed suit, posting a -$46.7 million loss versus -$36.6 million last year, down 27.4% on a relative basis. Diluted EPS was -$0.20, 25.0% worse than -$0.16, capturing the intensified losses from core operations and other financial obligations like the 2027 Notes. These dynamics underscore Gossamer Bio's history of substantial operating losses since inception, with expectations of continued significant deficits for the foreseeable future.
Cash flow from operations used $38.7 million, an improvement from $39.7 million YoY, equating to free cash flow given zero capital expenditures. This stabilization aligns with disciplined capital preservation, investing excess cash per policy for liquidity. However, ongoing losses signal persistent funding needs amid contractual obligations including leases and debt service.
Looking forward, management anticipates general and administrative expenses may rise to support R&D, commercial planning, and potential seralutinib commercialization if marketing approval is secured. The biotech model here emphasizes pipeline progress over near-term profitability, with liquidity managed conservatively while pursuing regulatory paths.